• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

Daily Derm Times: March 31, 2025

Key Takeaways

  • PASI and DLQI scores are interlinked, but stigma and residual effects can still affect patient quality of life.
  • The Q1 Dermatology Drug & Device Report provides insights into FDA approvals and pipeline updates for 2025.
SHOW MORE

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times logo

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

PASI and QoL: A New Approach to Treatment Goals

PASI and DLQI scores are closely linked, but stigma and residual effects may still impact patient QoL.

Q1 Dermatology Drug & Device Report: FDA Approvals & Pipeline Updates

Exclusive Q1 Report: A comprehensive look at the latest FDA approvals and pipeline developments in dermatology from the first quarter of 2025.

The Role of Medication in Effective Weight Loss

The integration of pharmacotherapy in obesity treatment provides a structured approach to weight loss for patients who struggle with traditional methods.

Celebrating Women’s History Month 2025 with Dermatology Times

This month and all year round, we recognize the strides and contributions of female leaders in dermatology.

Derm Dispatch: A Comprehensive Guide to Managing Eczema with Integrative Medicine

In the first Derm Dispatch episode, Renata Block, MMS, PA-C, and Peter Lio, MD, discuss integrative approaches to managing eczema, including the use of holistic treatments.

Melinda Gooderham, MD, MSc, FRCPC: Minimal Systemic Exposure of Delgocitinib Cream in Chronic Hand Eczema

At the 2025 AAD Annual Meeting, Gooderham shared data on the negligible systemic exposure of delgocitinib cream for chronic hand eczema.

Patients with Vitiligo Have a Lower Risk of Developing Serious Infections, New Poster Finds

Compared to patients with rheumatoid arthritis and atopic dermatitis, those with vitiligo had a lower incidence of major adverse effects.

Related Videos
© 2025 MJH Life Sciences

All rights reserved.